| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococci (coagulase-negative + methicillin-resistant) |
- |
- |
0.5 － 1 |
Linezolid (PNU-100766, U-100766, Zyvox)  |
193 |
| Staphylococci (coagulase-negative + methicillin-resistant) |
- |
- |
0.5 － 1 |
PH-027 |
193 |
| Staphylococci (coagulase-negative + methicillin-resistant) |
- |
- |
1 － 2 |
Vancomycin (Vancocyn, Lyphocin) |
89 |
| Staphylococci (coagulase-negative + methicillin-resistant) |
- |
- |
2 － 4 |
Mannopeptimycins (ε) |
89 |
| Staphylococci (coagulase-negative + methicillin-resistant) |
- |
- |
2 － ? |
Vancomycin (Vancocyn, Lyphocin) |
193 |
| Staphylococci (coagulase-negative + methicillin-resistant) |
- |
- |
4 － 8 |
Mannopeptimycins (γ) |
89 |
| Staphylococci (coagulase-negative + methicillin-resistant) |
- |
- |
4 － ? |
Mannopeptimycins (δ) |
89 |
| Staphylococci (coagulase-negative + methicillin-resistant) |
- |
- |
32 － 64 |
Mannopeptimycins (β) |
89 |
| Staphylococci (coagulase-negative + methicillin-resistant) |
- |
- |
128 － >128 |
Mannopeptimycins (α) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.015 |
0.03 |
0.015 － 0.03 |
AC98-6446 |
175 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.015 |
0.5 |
≤0.004 － 4 |
Gemifloxacin |
268 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
0.06 |
≤0.015 － 0.06 |
Dalbavancin |
72 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
0.12 |
≤0.03 － 0.5 |
Imipenem |
371 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
0.5 |
≤0.016 － 2 |
Moxifloxacin (BAY 12-8039, Avelox) |
207 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
0.5 |
0.12 － 1 |
DC-159a |
268 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
1 |
0.015 － 8 |
Garenoxacin (T-3811, BMS-284756) |
268 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
≤0.06 |
≤0.06 |
≤0.06 － >16 |
Gentamicin (Gentamycin, Garamycin) |
73 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.12 |
0.008 － 1 |
Imipenem |
102 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.12 |
0.015 － 4 |
Garenoxacin (T-3811, BMS-284756) |
102 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.12 |
0.03 － >128 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
162 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.25 |
≤0.06 － 0.5 |
TAK-599 |
162 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.5 |
≤0.03 － >8 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
73 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
1 |
0.03 － 4 |
Gatifloxacin (Tequin) |
207 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
1 |
0.03 － 8 |
Moxifloxacin (BAY 12-8039, Avelox) |
268 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.12 |
≤0.06 － 0.25 |
Oxacillin (Prostaphilin, Bactocil, Prostaphlin) |
73 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
≤0.12 |
≤0.12 |
≤0.12 － 0.25 |
Gentamicin (Gentamycin, Garamycin) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.25 |
0.06 － 0.25 |
Levofloxacin (Levaquin, Quixin) |
16 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.25 |
0.06 － 0.5 |
Daptomycin (Cubicin) |
16 |